Your eligibility for the study will be assessed based on specific health criteria

Medical tests will be performed, including lung function tests to measure your FEV1 (amount of air you can exhale in one second)

Your medical history of COPD (chronic lung disease) will be reviewed

Blood tests will check your eosinophil level (type of white blood cell)

You will be randomly assigned to receive either Tezspire or a placebo (inactive substance)

Neither you nor your doctor will know which treatment you are receiving

The medication will be given as an injection under the skin (subcutaneous injection)

The study will last for 76 weeks (approximately 1.5 years)

You will receive regular injections of either Tezspire 210 mg or placebo

Your current inhaled medications for COPD will be continued as prescribed

Regular clinic visits to check your lung function

Completion of questionnaires about your symptoms and quality of life

Monitoring of any breathing problems or COPD flare-ups

Blood samples will be collected to measure drug levels and check for antibodies

Your overall health and any side effects will be monitored throughout the study

Final assessment of your lung function and symptoms at week 76

Review of any breathing problems or COPD flare-ups during the study period

Final blood tests and health checks

Completion of final quality of life questionnaires